If you have been reading about RP-HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-26. Numbers and descriptions here follow the published literature rather than marketing material.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
Copper takes part in redox chemistry, and the same property that makes it useful in enzymes can generate reactive oxygen species when the ion is loosely bound. GHK chelates copper through imidazole, amino, and amide nitrogen donors, which reduces the amount of free copper in solution. Whether that chelation is protective, neutral, or harmful in a given tissue is not settled. Laboratory assays report both antioxidant and pro-oxidant behavior, depending on the conditions and the readout used.
Published work on GHK-Cu is dominated by in vitro experiments and small animal studies. Human trials tend to be short and small, with endpoints such as skin appearance rather than clinical outcomes. Review articles often summarize the same underlying laboratory findings, which can make the evidence base look broader than it is. Several basic questions remain open: the concentration of the intact complex in human tissue, the route by which it crosses the skin barrier, and whether effects seen in culture produce measurable changes in people.
| Property | Value | Notes |
|---|---|---|
| Long-term storage | -20 °C | Dry powder, sealed and protected from light |
| Working storage | 2 to 8 °C | Short-term holding; avoid repeated warming cycles |
| Purity assay | Reversed-phase HPLC with UV detection | Detection commonly near 214 nm |
| Copper assay | ICP-OES or atomic absorption | Confirms metal content and the metal-to-peptide ratio |
| Visible absorption | Roughly 520 to 600 nm | Rapid indicator of complex integrity |
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence of three amino acids. The peptide was first isolated from human plasma in 1973 during research on factors that influence tissue repair in liver. Its ability to bind copper ions became a central point of interest because the metal changes the peptide's chemistry and its behaviour in laboratory systems. Today the compound appears in cosmetic formulations, cell-culture studies, and biochemistry literature under several names.
The peptide sequence places a histidine in the middle, and this residue dominates metal binding. Copper(II) coordinates through the imidazole nitrogen of histidine and the terminal amino group, forming a stable chelate ring system. Loss of the copper ion leaves the free tripeptide, which has different solubility and reactivity. This structural detail matters because assays that measure only the peptide backbone can miss whether copper is still bound to it.
Several names circulate for the same material, which complicates literature searches. Cosmetic ingredient lists often use copper tripeptide-1, while older biochemistry papers use glycyl-L-histidyl-lysine or its abbreviation GHK. The copper complex is sometimes written as GHK-Cu(II) to make the oxidation state explicit. Terminology is not fully standardized, so matching a compound across sources requires attention to the exact sequence, the counterion, and the stated copper content. Reviews that compare studies must account for these naming differences before drawing conclusions.
Copper peptide solutions tend to resist degradation better than many free peptides, because the bound metal protects the N-terminus and reduces susceptibility to some peptidases. Backbone hydrolysis, oxidation of the histidine imidazole ring, and photochemical reactions remain the principal degradation routes. Aqueous solutions are generally most stable near neutral to mildly acidic pH, while strongly alkaline conditions accelerate hydrolysis. Light exposure is usually avoided, since both the peptide and the copper center can take part in photochemical processes. Stability data published by suppliers often describe short-term behavior rather than multi-year shelf life.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, frequently paired with mass spectrometry to confirm the molecular ion. Copper content is measured separately, typically by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the chromatographic signal reports the peptide rather than the metal. Ultraviolet-visible spectroscopy provides a fast check on complex formation, since copper(II) peptide complexes absorb in the visible region. Elemental analysis and amino acid analysis are used less often but remain useful for reference standards. A gap between reported peptide purity and measured copper content is a recurring source of confusion.
Material described as GHK-Cu appears in several distinct markets, including cosmetic ingredients, laboratory reagents, and consumer products, and the quality expectations attached to each differ. A certificate of analysis generally reports peptide purity by chromatography, copper content, appearance, and residual solvents or counterions. Counterion identity matters, because the complex is usually supplied as an acetate or a similar salt, and the counterion contributes to the measured mass. Independent verification of sequence and metal stoichiometry is advisable when a material is used for quantitative work. Batch-to-batch variation is common and should be documented rather than assumed negligible.
In prehistoric and protohistoric times, over a period of approximately 500,000 years, the area of present-day Poland was intermittently inhabited by members of the genus Homo. The earliest evidence of Homo erectus activity in the form of microlith artifacts was discovered at Trzebnica, in Lower Silesia. It remains the oldest archeological site in the country, dating back to the Lower Paleolithic period of the Stone Age. The southern regions of Poland were subsequently penetrated by sporadic groups of Neanderthals. Their presence was confirmed by the stone tools unearthed in caves of the Kraków-Częstochowa Upland, a limestone formation with hills, cliffs and valleys that came to be known as the Polish Jura. The arrival of Homo sapiens and anatomically modern humans coincided with the climatic discontinuity at the end of the Last Glacial Period (Weichselian glaciation) around 10,000 BC, when Poland became warmer and habitable. It allowed various groups of early humans to pass the Sudeten Mountains through the Moravian Gate and the Kłodzko Valley into Lower Silesia. The Neolithic period ushered in the Linear Pottery culture, whose founders belonged to the Danubian culture and migrated from the Danube River area beginning about 5500 BC. This culture was distinguished by the establishment of the first settled agricultural communities in modern Polish territory. Later, between about 4400 and 2000 BC, the native post-Mesolithic populations would also adopt and further develop the agricultural way of life. Excavations indicated broad-ranging development in the New Stone Age.
Not Now. There is no counterbalance." Two American Neoconservative thinkers, Robert Kagan and William Kristol, completely agree: "Today’s international system is built not around a balance of power but around American hegemony." Christopher Layne published two articles on the post-Cold War case, "The Unipolar Illusion…" (1993) and "The Unipolar Illusion Revisited" (2006). The former predicted imminent anti-American balancing as the balance of power theorists expected; the latter explains "why balance of power theorists got it wrong." Finally, Dall'Agnol analyzes, through a critical bias, the implications of unipolarity for balancing behavior. In order to do so, he discusses the dynamics of balance of power theory, assumed to be inoperative in the post-Cold War period by main academic debates over unipolarity: i) unipolar stability; ii) balance of threats; iii) soft balancing; iv) liberal institutionalism. He then argues that these approaches, including the unipolar illusion view, tied to the balance of power theory, overestimate the effects of unipolarity on balancing behavior of other states. Concluding that balance of power dynamics, especially those of hard balancing, are still observed in the post-Cold War era, he criticizes two main conclusions from the literature: i) that balancing became inoperative and; ii) that the only available strategies to other states are soft balancing and bandwagoning. In sum, this conclusion has directly implication on strategies available both to the United States and to its main competitors.
== History == Opicapone was authorised for medical use in the European Union in June 2016. In February 2017, its developer Bial sold exclusive marketing rights for the United States and Canada to Neurocrine Biosciences for an initial payment of US$30 million. Opicapone was authorised for medical use in the United States in April 2020. Opicapone was approved based on evidence from two clinical trials (Trial 1/ NCT01568073, and Trial 2/NCT01227655) of 522 participants with Parkinson's disease (PD) whose symptoms were not well controlled while receiving their regular PD treatment. Trial 1 was conducted at 104 sites in 19 European countries, and Trial 2 was conducted at 69 sites in Argentina, Australia, Belgium, Chile, Czech Republic, Estonia, India, Israel, South Korea, Russia, South Africa and UK. There were two 12-week trials conducted in Parkinson's disease (PD) participants with inadequate control of their Parkinson's symptom ("off" time) while receiving carbidopa/levodopa PD medications. Participants were randomly selected to receive either opicapone or a placebo capsule once a day. Neither the participants nor the health care providers knew which treatment was being given until the trial was completed. In all of the trials, the participants kept daily diaries of the number of hours of "off" time for the three days before the evaluation visit. The benefit was evaluated by measuring the change from baseline in total daily "off" time in opicapone- and placebo-receiving participants.
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have shown promise in treating anhedonia by modulating dopaminergic signaling within the brain's reward system, which is often disrupted in conditions like obesity and type 2 diabetes. These agents help normalize insulin resistance and reduce cravings, potentially alleviating the diminished pleasure response characteristic of anhedonia through their influence on reward-related behaviors. By decreasing neurocortical activation in response to high-calorie food cues and higher rewards, GLP-1RAs offer a novel therapeutic approach for motivation and reward-processing disorders, extending their use beyond metabolic regulation to address anhedonic symptoms.
Sources: en.wikipedia.org
== Efficacy == A Cochrane systematic review assessed the effect of alpha-glucosidase inhibitors (acarbose and voglibose) in people with impaired glucose tolerance, impaired fasting blood glucose, elevated glycated hemoglobin A1c (HbA1c). Trials of people diagnosed with “metabolic syndrome” or such with an intervention duration of less than one year were excluded from this systematic review. The authors concluded that “[i]n people with intermediate hyperglycaemia the use of alpha‐glucosidase inhibitors [including voglibose] reduces or delays the incidence of type 2 diabetes mellitus”, but “[t]here is no firm evidence that alpha‐glucosidase inhibitors prevent cardiovascular mortality and morbidity.” The results of this review are overall rather uncertain because of “systematic errors in some of the included trials, the overall low number of trials for a particular outcome, imprecise results and missing data of one included trial [“EDIT 1997”, which investigated acarbose, not voglibose].” The authors investigated in total two studies on voglibose, one which compared it to placebo, one which compared it to diet plus exercise. While the latter one was criticized for imprecision, in the first one, the amount of patients developing diabetes mellitus type 2 was reduced by more than 50% in patients treated with voglibose (5.6%) compared to those treated with placebo (12%). However, this was classified as “low‐certainty evidence”.
The report acknowledged that "volunteers or mercenaries" entered Georgia from Russia before the Georgian military operation, adding that "some" non-peacekeeping Russian troops were present in South Ossetia and that Russian air force was already acting against Georgia before the public decision to participate in the conflict was made by the Russian leadership at 14:30 on 8 August.
Beckman Coulter Diagnostics [1] Find out about the latest breakthroughs in clinical diagnostics and laboratory operations. SCIEX, a provider liquid chromatography-mass spectrometry instrumentation, offers P.A.C.E.® credits through its in-house training classes 4CEUINC (Continuing Education Unlimited) - Providing Online & Home Study Lab CE Courses LabCE.com Laboratory Continuing Education MediaLab, Inc. Online ASCLS P.A.C.E. credits National Laboratory Training Netword, provided through the CDC COLA LabUniversity P.A.C.E. credits
Sources: en.wikipedia.org
== Cause == Scurvy, including subclinical scurvy, is caused by a deficiency of dietary vitamin C since the human liver is unable to synthesize vitamin C. Provided the diet contains sufficient vitamin C, the lack of working L-gulonolactone oxidase (GULO) enzyme has no significance. In modern Western societies, scurvy is seldom present in average adults, although underfed people (drug users, the homeless, neglected children and geriatrics) are affected. Virtually all commercially available baby formulas contain added vitamin C, preventing infantile scurvy. Human breast milk contains sufficient vitamin C if the mother has an adequate intake. Commercial milk is pasteurized, a heating process that destroys the natural vitamin C content of the milk. Scurvy is one of the accompanying diseases of malnutrition (other such micronutrient deficiencies are beriberi and pellagra) and thus is still widespread in areas of the world dependent on external food aid. Although rare, there are also documented cases of scurvy due to poor dietary choices by people living in industrialized nations.
=== Cardiovascular === Although cardiovascular involvement depends significantly on the diagnosed subtype of EDS, several co-morbidities and symptoms are closely linked to the disorder as a whole. Some studies suggest that structural abnormalities are not the root cause of the vast majority of cardiac symptoms, but rather, dysautonomia is the primary culprit. Associated symptoms can include, but are not limited to, palpitations, near-syncope and syncope, heat intolerance, and difficulty managing blood pressure and heart rate. One study published in 2013 found that patients with EDS were more likely to also be diagnosed with postural orthostatic tachycardia syndrome, more commonly known as POTS. Weak connective tissues in the heart can cause problems with valve structure and function. Mitral valve prolapse and regurgitation and aortic root dilation are found more commonly in EDS patients and others with similar connective tissue disorders. In some cases, EDS manifests within the vasculature as well. Major artery aneurysms and dissections are sometimes seen as a result of faulty structural integrity.
=== Applications and operating systems === 1979: Apple II: VisiCalc (first spreadsheet program and killer app) 1979: CP/M systems: WordStar 1982: WordStar ported to CP/M-86 and IBM PC compatible/MS-DOS 1983: IBM PC compatible/MS-DOS: Lotus 1-2-3 (spreadsheet) 1985: Macintosh: Microsoft Excel (first WYSIWYG spreadsheet) and Microsoft Word (WYSIWYG word processor), Aldus (now Adobe) PageMaker (first desktop publishing program) 1985: AmigaOS: Deluxe Paint, Video Toaster, Prevue Guide 1987/1989: Microsoft Excel and Microsoft Word ported to Microsoft Windows 1993: Acorn Archimedes: Sibelius
Sources: en.wikipedia.org
Dry powder is best kept cold, dark and sealed, typically at -20 °C for long-term storage or 2 to 8 °C for material in regular use. Vials should be warmed to room temperature before opening to prevent moisture condensing on the contents. Aqueous stock solutions degrade faster and are usually prepared fresh.
The colour comes from electronic transitions between the copper ion and the surrounding peptide nitrogen atoms. The resulting absorption sits in the visible region, giving the solid and its solutions a blue to violet appearance. Loss of colour can indicate that the copper has dissociated from the peptide.
Chromatography establishes the identity and purity of the peptide, while elemental analysis establishes the copper content. The two results should agree with a one-to-one ratio. Visible spectroscopy adds a quick check that the complex itself is intact.
It is not approved as a pharmaceutical in major markets and is used mainly as a cosmetic ingredient and a laboratory reagent. Regulatory status varies by country and by the product category in which it appears. Claims about therapeutic effects should be treated separately from permitted cosmetic labeling.